Media enquiries: Prof. Nikolai
Petrovsky, nikolai.petrovsky@flinders.edu.au
cell phone:
VAXINE ANNOUNCES
MAJOR PROGRESS IN TRIAL OF WORLD’S FIRST
SWINE FLU VACCINE
Vaxine announced that its investigators at Flinders Medical Centre in Adelaide have
started giving trial subjects their critical second swine flu vaccine booster.
“We are excited to continue to lead the world in clinical tests of swine flu vaccine,” said
Professor Nikolai Petrovsky, Vaxine Research Director. “We will soon know outcomes of
the first immunisation from blood results but are working on the assumption that two
immunisations will be required.”
For these trials, Vaxine is using its proprietary Advax ™ sugar-based vaccine enhancer
with influenza antigen from US partner, Protein Sciences Corporation. The trial will provide
the world’s first insight into what dose and how many boosters are required for protection.
“The only current benchmark to what might be needed is Sanofi’s H5N1 vaccine that
required 2x90 microgram doses to be effective”
said Prof. Petrovsky. “This is six times
higher than what most vaccine manufacturers
are planning for their swine flu vaccines.
Vaxine’s soon to be released trial data is going to be critical to help government authorities
identify the optimum vaccine dose. If the swine flu vaccine turns out anything like the H5N1
vaccine, then the global swine flu vaccine shortfall is going to be immense, with supply being
only one sixth of current projections.”
Vaxine with funding assistance from AusIndustry and the US National Institute of Health
has developed a novel vaccine enhancement technology called Advax™ that when co-
administered boosts vaccine effectiveness while reducing dose. Using this technology, limited
vaccine can be stretched further, enabling swine flu vaccine supplies to better meet global
meets.
Vaxine’s sugar-based Advax™ enhancement
technology has little in common with
vaccine adjuvants that have received considerable negative press because of safety and
side-effect concerns. Clinical studies of Advax™ confirm its unique ability to enhance
vaccine effectiveness without side-effects. Vaxine is currently establishing partnerships with
vaccine manufacturers around the world to make Advax™ technology globally available,
thereby providing a safe and effective alternative to current vaccine ingredients such as
aluminium and mercury.
About Vaxine Pty Ltd
Established in 2002, Vaxine is an Australian-based biotechnology company specialising in development of
novel vaccine technologies. Lead products in late-stage development include vaccines for seasonal and
pandemic influenza, Japanese encephalitis, hepatitis B, and bee sting allergy plus the
Advax™ vaccine
enhancement technology. More information on Vaxine and its projects can be found at http://vaxine.com.au
NEWS 
